Cargando…
Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history
Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892947/ https://www.ncbi.nlm.nih.gov/pubmed/29662320 http://dx.doi.org/10.2147/JAA.S107982 |